BCM
KLDO

BlueCrest Capital Management’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

BlueCrest Capital Management’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11,412
Closed -$165K – 1163
2019
Q1 		$165K Buy
+11,412
New +$157K 0.01% 994

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BlueCrest Capital Management's KLDO Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2019, closing a stake of 11,412 shares — an estimated $165K sold.

BlueCrest Capital Management first reported a position in KLDO in Q1 2019 and held it in 1 quarter. The position peaked at $165K in Q1 2019. 37 funds tracked by Wall St. Rank hold KLDO as of Q2 2019.

  • BlueCrest Capital Management reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 11,412 Kaleido Biosciences, Inc. Common Stock shares in Q2 2019, an estimated $165K.
  • BlueCrest Capital Management first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • BlueCrest Capital Management's Kaleido Biosciences, Inc. Common Stock position peaked at $165K in Q1 2019.
  • 37 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.